Parkwoods Wealth Partners LLC Buys Shares of 1,531 Abbott Laboratories $ABT

Parkwoods Wealth Partners LLC purchased a new position in shares of Abbott Laboratories (NYSE:ABT) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 1,531 shares of the healthcare product maker’s stock, valued at approximately $208,000.

Several other large investors also recently made changes to their positions in the stock. Brighton Jones LLC lifted its holdings in shares of Abbott Laboratories by 10.1% during the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock worth $5,850,000 after buying an additional 4,755 shares during the last quarter. Fragasso Financial Advisors Inc boosted its holdings in Abbott Laboratories by 3.2% in the 1st quarter. Fragasso Financial Advisors Inc now owns 6,150 shares of the healthcare product maker’s stock valued at $816,000 after purchasing an additional 188 shares during the period. Merit Financial Group LLC grew its position in Abbott Laboratories by 7.9% in the 1st quarter. Merit Financial Group LLC now owns 54,329 shares of the healthcare product maker’s stock worth $7,207,000 after purchasing an additional 3,989 shares during the last quarter. ST Germain D J Co. Inc. increased its holdings in shares of Abbott Laboratories by 2.3% during the 1st quarter. ST Germain D J Co. Inc. now owns 21,101 shares of the healthcare product maker’s stock worth $2,799,000 after purchasing an additional 469 shares during the period. Finally, HBW Advisory Services LLC raised its position in shares of Abbott Laboratories by 53.9% during the first quarter. HBW Advisory Services LLC now owns 3,263 shares of the healthcare product maker’s stock valued at $433,000 after buying an additional 1,143 shares during the last quarter. Institutional investors own 75.18% of the company’s stock.

Insider Activity

In other news, CFO Philip P. Boudreau sold 5,550 shares of the firm’s stock in a transaction on Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the transaction, the chief financial officer directly owned 51,003 shares in the company, valued at $6,862,453.65. This trade represents a 9.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.46% of the stock is owned by corporate insiders.

Abbott Laboratories Stock Up 0.6%

NYSE ABT opened at $133.97 on Wednesday. The stock has a fifty day moving average of $131.48 and a 200-day moving average of $131.22. The stock has a market capitalization of $233.17 billion, a P/E ratio of 16.79, a price-to-earnings-growth ratio of 2.52 and a beta of 0.69. Abbott Laboratories has a 52 week low of $110.86 and a 52 week high of $141.23. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, meeting the consensus estimate of $1.26. The company had revenue of $11.14 billion during the quarter, compared to analysts’ expectations of $11.01 billion. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The business’s revenue for the quarter was up 7.4% on a year-over-year basis. During the same period last year, the firm earned $1.14 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. On average, equities research analysts forecast that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, November 17th. Stockholders of record on Wednesday, October 15th will be given a $0.59 dividend. This represents a $2.36 annualized dividend and a dividend yield of 1.8%. The ex-dividend date is Wednesday, October 15th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 29.57%.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Raymond James Financial reduced their price objective on Abbott Laboratories from $142.00 to $141.00 and set an “outperform” rating for the company in a research report on Friday, July 18th. Royal Bank Of Canada raised their price objective on Abbott Laboratories from $145.00 to $147.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 15th. Leerink Partners assumed coverage on Abbott Laboratories in a research report on Monday, June 16th. They issued a “market perform” rating and a $143.00 price objective for the company. Evercore ISI raised their price objective on Abbott Laboratories from $140.00 to $145.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 8th. Finally, Wells Fargo & Company dropped their target price on Abbott Laboratories from $147.00 to $142.00 and set an “overweight” rating for the company in a report on Friday, July 18th. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $145.22.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.